NHLBI EIA R35 Guide
Updated 5 official sources
Quick Answer: RFA-HL-26-003 NHLBI EIA eligibility turns on 7 checks: active NHLBI R01-equivalent portfolio, qualifying ESI R01, single-PD/PI condition, effort commitment, HLBS research-program fit, $700,000 annual direct-cost cap, and seven-year plan.
Full answer and how we checked it
The last due date is February 19, 2027, and an award means giving up most of your other NHLBI single-PI grants.
Who this is for: NHLBI-funded emerging investigators, department chairs, research administrators, grant strategists, and sponsored-research offices deciding whether the NHLBI EIA R35 is the right route.
Data note: This guide uses the official NIH RFA-HL-26-003 NOFO, Grants.gov listing 353822, NIH clinical-trial policy pages, NIH RePORTER (opens in a new tab) award records, and Grantsights award-data signals checked on May 19, 2026 and rechecked October 9, 2026.
In this guide
- 7 RFA-HL-26-003 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- The Fine Print on Eligibility
- What You Give Up if You Win
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This Application Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day NHLBI EIA Readiness Plan
- Who Has Received the NHLBI EIA
- 6 Final Research Checks Before Submission
- 4 Decision Questions Before Drafting
- 3 Last-Mile Checks For NHLBI Investigators
- Sources
Quick Facts
- Agency
- HHS
- Deadline
- Apr 28, 2027
- Status
- Open
Assistance Listing 93.233: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.233, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 131
- Avg Award (whole listing)
- $3,121,419
- Median Award (whole listing)
- $2,702,841
Data last verified: May 21, 2026
According to NIH RFA-HL-26-003 (opens in a new tab), the NHLBI Emerging Investigator Award supports experienced PDs/PIs who are currently PDs/PIs on at least two NHLBI R01-equivalent awards, with one being an NHLBI-funded NIH Early Stage Investigator R01 award. NIH marks the R35 as Clinical Trial Optional.
This route is not for every strong early-career researcher. The eligibility screen is exacting, and the award is meant to support an NHLBI-relevant research program rather than a single project.
Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI clinical trial pilot guide, NHLBI Catalyze R33 guide, and the Grantsights grant database.
7 RFA-HL-26-003 Eligibility Stop Checks
| Stop check | Strong NHLBI EIA signal | Red flag |
|---|---|---|
| R01-equivalent portfolio | At least two NHLBI R01-equivalent awards | Portfolio does not qualify |
| ESI R01 | One qualifying NHLBI-funded ESI R01 exists | No qualifying ESI R01 |
| Award status | Required award status rules are met | No-cost extension risk |
| Effort | Six person months can be committed | Effort cannot be protected |
| Program fit | HLBS research program is coherent | Single-project story |
| Budget | Up to $700K direct costs per year fits | Budget exceeds or lacks rationale |
| Term | Seven-year program plan is credible | Plan is too narrow |
Strong investigators sometimes assume "emerging" means broad early-career eligibility. For this NOFO, the existing NHLBI award portfolio is the gate.
5 Source Facts Applicants Should Know
According to NIH, the NHLBI EIA is intended to support a research program, rather than a research project, and may provide support for up to 7 years.
According to NIH, the PD/PI must be on at least two NHLBI R01-equivalent awards, defined as R01, DP1, or DP2. One must be an NHLBI-funded ESI R01. NIH also says the PD/PI must commit at least six person months throughout the award.
| Fact | Source-backed read |
|---|---|
| Funding number | RFA-HL-26-003 |
| Activity code | R35 Outstanding Investigator Award |
| Clinical trial status | Clinical Trial Optional |
| Budget | Up to $700,000 direct costs per year |
| Project period | Up to 7 years |
| Due dates | February 19, 2026 (passed); February 19, 2027 (last) |
| Review for February 2027 | July 2027 review, October 2027 council, December 2027 earliest start |
| Expiration | April 29, 2027 |
| Funding plan | Up to 20 new R35 awards and up to $20 million in total costs a year in FY2026 to FY2028, shared with a companion NOFO |
| Live listing | Grants.gov listing 353822 |
Two date details matter. The NOFO still says a letter of intent is due 30 days before the deadline, but NIH stopped requesting or accepting letters of intent under NOT-OD-26-019 (opens in a new tab), so there's nothing to send. And the February 2027 round has no resubmission date, because only new applications are allowed.
The Fine Print on Eligibility
NHLBI checks eligibility itself after the due date, and the NOFO (opens in a new tab) is more specific than "two R01s." At least one of the two qualifying R01-equivalent awards must be single-PD/PI, must not be in a no-cost extension, and must not be an NIH-defined clinical trial unless it's a mechanistic trial. The other qualifying award can be multi-PD/PI, in a first no-cost extension, or a clinical trial. One of the two must be an NHLBI-funded Early Stage Investigator R01. Multi-PD/PI applications aren't accepted, and an application missing its letters of support won't go to review.
The six person months is defined precisely: 50% effort on a 12-month appointment, 66.67% on a 9-month appointment, or 100% on a 6-month appointment, held for the whole award. Effort on teaching, administration, and clinical duties doesn't count toward it.
"Clinical Trial Optional" also has a limit. Mechanistic trials are allowed, but Phase I, II, III, or T4 non-mechanistic clinical trials make an application nonresponsive.
What You Give Up if You Win
NHLBI expects the EIA to replace your current NHLBI single-project, single-PD/PI research grants, and the AOR must acknowledge that in the application. Training grants, resource grants such as P30, R24, and U24, contracts, cooperative agreements, SBIR/STTR, conference grants, program project and center grants, and Catalyze grants are exempt. NHLBI won't fund new individual research grants for you during the EIA except near its end or during a no-cost extension.
You can submit an R01 and an EIA in parallel. If both are selected, you take one or the other. The award amount is set by NHLBI and is expected to be commensurate with your current NHLBI support, so the $700,000 cap isn't a target.
What NIH Doesn't Tell You
Within 21 days, answer 4 practical questions. First, this is a portfolio eligibility problem before it is a writing problem. If the R01-equivalent and ESI R01 rules fail, a good program vision cannot fix the application.
Second, the award must read as a program. An investigator whose related NHLBI-funded projects form a clear HLBS program may fit. An investigator with two unrelated projects may need a stronger program architecture first.
Third, the effort commitment is strategic. Six person months is a real commitment, and the institution should understand the tradeoff.
Fourth, reviewers score the investigator as much as the plan. The NOFO-specific questions ask how the PD/PI has shown outstanding productivity, how past work has advanced HLBS research, whether the program is broad and ambitious enough, whether the PD/PI shows promise as a mentor and in professional service, and whether the institutional letter of support commits to the PD/PI for the whole award.
6 Evidence Assets That Make This Application Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the eligibility memo. List current NHLBI R01-equivalent awards, ESI R01 status, PD/PI role, award status, and no-cost extension details.
Asset 2 is the program-vision memo. Explain the unifying HLBS research program across projects.
Asset 3 is the consolidation map. Show how current and future research directions fit the R35 program rather than competing projects.
Asset 4 is the effort plan. Show six person months, leadership roles, lab structure, mentoring, and institutional support.
Asset 5 is the budget plan. Tie up to $700,000 direct costs per year to program needs.
Asset 6 is the route memo. Compare EIA R35 with new R01s, R01 renewals, OIA, R56, R21, clinical-trial NOFOs, and foundation routes.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| NHLBI EIA R35 | Eligibility and program vision both fit | R35 route fits |
| R01 renewal | One project needs continuation | Project route may fit |
| New R01 | New project is separate | Standard route may fit |
| OIA or other R35 | Investigator stage differs | Different R35 may fit |
| R21 or foundation | Idea is early or exploratory | Smaller route may fit |
Warning: if the applicant cannot prove ESI R01 and NHLBI R01-equivalent eligibility in one page, don't start with the EIA narrative.
6 Bad-Fit Signals
First, the PD/PI lacks two qualifying NHLBI R01-equivalent awards. Second, no qualifying ESI R01 exists. Third, the program is a collection of unrelated projects.
Fourth, effort cannot be protected. Fifth, budget is not tied to the research program. Sixth, clinical-trial status is unclear.
These signals are gate risks.
21-Day NHLBI EIA Readiness Plan
Days 1 through 3 should verify R01-equivalent awards, ESI R01 status, award status, effort, and clinical-trial boundary. Days 4 through 7 should write the eligibility and program-vision memos.
Days 8 through 12 should build consolidation, effort, and budget plans. Days 13 through 16 should compare EIA with R01, renewal, R21, and other R35 routes. Days 17 through 21 should complete NIH application checks and institutional commitment review.
Who Has Received the NHLBI EIA
5 new awards under RFA-HL-26-003 appear in FY2026 NIH RePORTER (opens in a new tab) records pulled by Grantsights on October 9, 2026. They came from the February 19, 2025 round, whose earliest start date was December 2025; awards from the February 2026 round can start no earlier than December 2026.
| Award | Organization | Program topic | FY2026 direct costs |
|---|---|---|---|
| R35HL184269 | Icahn School of Medicine at Mount Sinai | Hemogenic mesoderm heterogeneity and function | $699,955 |
| R35HL184260 | Henry Ford Health + Michigan State University Health Sciences | Circadian medicine for shift workers | $700,000 |
| R35HL184172 | University of Virginia | Imaging sodium in lymphatic disease | $597,526 |
| R35HL183578 | Stanford University | Endothelial and cardiomyocyte crosstalk in cardiomyopathy | $500,000 |
| R35HL183474 | Dana-Farber Cancer Institute | Clonal dynamics in hematopoiesis | $250,000 |
Grantsights analysis of those records and the earlier RFA-HL-23-005 awards shows first-year direct costs from about $170,000 to $721,000. That spread fits the NOFO's rule that the award tracks each investigator's existing NHLBI support. Topics run across heart, lung, blood, vascular, and sleep or circadian science, and most recipients are at academic medical centers or research institutes.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final checks. Check 1 is the NIH RFA-HL-26-003 NOFO (opens in a new tab). Check 2 is NIH application-guide compliance. Check 3 is NHLBI R01-equivalent portfolio. Check 4 is ESI R01 status. Check 5 is effort commitment. Check 6 is clinical-trial boundary.
You're ready when the team can state the two qualifying awards, ESI R01, program vision, effort commitment, budget, and route reason in 6 direct sentences.
4 Decision Questions Before Drafting
Within 21 days, ask 4 decision questions. Question 1: "Do you have at least two qualifying NHLBI R01-equivalent awards?" Question 2: "Is one a qualifying NHLBI ESI R01?" Question 3: "Can you commit six person months?" Question 4: "Does the work read as one research program?"
If question 1 or 2 fails, stop and plan around an R01 renewal or new R01 instead.
3 Last-Mile Checks For NHLBI Investigators
Within 21 days, run 3 last-mile checks. Check 1 is award-portfolio proof. Check 2 is program-vision proof. Check 3 is effort proof.
If those checks are weak, talk to NHLBI before building the narrative. A final note for applicants: write the EIA fit sentence before the overview. In 2 sentences, state the qualifying awards, ESI R01, HLBS program, effort, budget, and reason R35 is the best route.
Sources
- NIH RFA-HL-26-003 (opens in a new tab)
- NOT-OD-26-019 on letters of intent (opens in a new tab)
- NIH RePORTER (opens in a new tab), RFA-HL-26-003 and RFA-HL-23-005 awards pulled October 9, 2026
- NIH clinical trials policies and guidance (opens in a new tab)
- Grants.gov listing 353822 (opens in a new tab)
Largest awards active in FY2024
One row per recipient, its largest award | 131 Assistance Listing records | Avg: $3.1M
Beth Israel Deaconess Medical Center, Inc.
MA
Brigham & Womens Hospital Inc
MA
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Frequently Asked Questions
What does RFA-HL-26-003 support?
It supports NHLBI-funded emerging investigators with long-term flexible R35 support for an HLBS research program.
What eligibility rule is central?
NIH says the PD/PI must be on at least two NHLBI R01-equivalent awards, and one must be an NHLBI-funded ESI R01.
What is the budget cap?
Applications may request up to $700,000 in direct costs per year.
How long can support run?
Applications may request up to seven years.
When is the next due date?
February 19, 2027 is the only remaining due date. The February 19, 2026 date has passed, and the NOFO expires April 29, 2027.
Who should skip this route?
Skip it if the PD/PI does not meet the current NHLBI R01-equivalent and ESI R01 eligibility rules or cannot commit the required effort.
Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NIH K24 Midcareer Investigator Award Guide
NIH K24 midcareer investigator award eligibility guide for PA-24-188, 25% to 50% effort, mentoring proof, trial limits, and route choice.
PAR-25-032 NHLBI R34 pilot eligibility Guide
PAR-25-032 NHLBI R34: $450,000 direct over 3 years, new due dates through March 16, 2027, and what 151 past pilots led to.
NHLBI R61/R33 Early Phase Eligibility Guide
NHLBI R61/R33 guide: 8 checks for PAR-25-026, Phase 0/I trials, HLBS fit, $250K R61 cap, $1.515M R33 cap, and milestones.
NIGMS MIRA R35 Eligibility Guide 2026
NIGMS MIRA R35 eligibility guide for PAR-26-121, investigator program scope, clinical trial optional status, budget fit, and R01 choice.
ACF Recent Awards: FY2026 Grants by Program
ACF signed 4,251 new grant awards worth $60.3 billion in FY2026, and 96% of the money was formula funding. See the discretionary and Head Start winners.
ACL Recent Awards: FY2026 Grants by Program and Recipient
ACL signed 2,515 new grants worth $2.23 billion in FY2026, and 88% went to states by formula. See the competitive, Title VI and independent living awards.